This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

American Home Products Meets Expectations; Sets Huge Fen-Phen Charge

Earnings Scorecard
Actual Estimated* Year-Ago
$0.53 $0.53 $0.46

Drug maker American Home Products (AHP - Get Report) reported fourth-quarter earnings Thursday that matched Wall Street's expectations.

The maker of pharmaceuticals, consumer health care and agricultural products reported earnings of $704.3 million, or 53 cents a share, compared with $602.7 million, or 46 cents a share, in the same quarter one year before. The results matched a consensus estimate of 19 Wall Street analysts polled by First Call/Thomson Financial.

However, the Madison, N.J.-based company also said it would take a higher-than-expected charge of $7.5 billion due to a lawsuit settlement for Fen-Phen, a popular slimming drug that has been linked with certain pulmonary and heart problems. The company originally estimated that the lawsuit would cost the company $4.75 billion.

"Although it will cost more than we originally expected, we believe it is clearly in the best interest of AHP shareholders to resolve the diet drug litigation quickly," the company said in a press release. "We are confident that no further charges will be required and that the strength of our business will enable us to meet earnings targets and all other business targets despite higher interest costs."

The company's stock closed at $54.75 Wednesday on the New York Stock Exchange.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AHP $11.21 -2.00%
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs